Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - ceftriaxone sodium 269.9mg (present as 0.298g ceftriaxone na*3.5h2o. eq 0.269g of ceftriaxone na anhyd or 0.25g ceftriaxone anhy) - powder for injection - 250 mg - active: ceftriaxone sodium 269.9mg (present as 0.298g ceftriaxone na*3.5h2o. eq 0.269g of ceftriaxone na anhyd or 0.25g ceftriaxone anhy)

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - ceftriaxone sodium 539.7mg (present as 0.5965g ceftriaxone na*3.5h2o. eq 0.53965g of ceftriax na anh or 0.5g ceftriaxone anhyd) - powder for injection - 500 mg - active: ceftriaxone sodium 539.7mg (present as 0.5965g ceftriaxone na*3.5h2o. eq 0.53965g of ceftriax na anh or 0.5g ceftriaxone anhyd)

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

viatris limited - ceftriaxone sodium 2.158 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - powder for infusion - 2 g - active: ceftriaxone sodium 2.158 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - infections caused by pathogens sensitive to ceftriaxone e.g.: - sepsis; - meningitis; - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms; - renal and urinary tract infections; - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; - genital infections, including gonorrhoea. - perioperative prophylaxis of infections.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime;  ;   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 291mg equivalent to 250 mg ceftazidime;   - powder for injection - 250 mg - active: ceftazidime pentahydrate 291mg equivalent to 250 mg ceftazidime   excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 2.328 g equivalent to 2g ceftazidime;  ;   - powder for injection - 2 g - active: ceftazidime pentahydrate 2.328 g equivalent to 2g ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 582mg equivalent to 500 mg ceftazidime;  ;   - powder for injection - 500 mg - active: ceftazidime pentahydrate 582mg equivalent to 500 mg ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftriaxone sodium 1.19 g equivalent to ceftriaxone 1 g - powder for injection - 1 g - active: ceftriaxone sodium 1.19 g equivalent to ceftriaxone 1 g - ceftriaxone sodium is indicated for the treatment of lower respiratory tract infections when caused by susceptible aerobic organisms

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftriaxone sodium 2.39 g equivalent to ceftriaxone 2 g - powder for injection - 2 g - active: ceftriaxone sodium 2.39 g equivalent to ceftriaxone 2 g - ceftriaxone sodium is indicated for the treatment of lower respiratory tract infections when caused by susceptible aerobic organisms

Estados Unidos - inglês - NLM (National Library of Medicine)

cardinal health - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 2 g